Corium International (NASDAQ:CORI) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.
Several other equities analysts have also issued reports on the company. Zacks Investment Research lowered Corium International from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright set a $14.00 price target on Corium International and gave the company a “buy” rating in a research note on Wednesday, December 27th. Needham & Company LLC cut their price target on Corium International from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, December 26th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price target on shares of Corium International in a research note on Friday, December 22nd. Finally, Jefferies Group set a $10.00 price target on Corium International and gave the company a “buy” rating in a research note on Sunday, October 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $12.86.
Corium International (NASDAQ:CORI) opened at $9.61 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 6.80 and a current ratio of 7.04. Corium International has a one year low of $2.67 and a one year high of $12.32. The stock has a market capitalization of $347.09, a price-to-earnings ratio of -5.75 and a beta of 1.26.
A number of large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in Corium International by 33.7% in the third quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 22,285 shares during the period. California State Teachers Retirement System acquired a new position in Corium International in the second quarter valued at about $263,000. State Street Corp acquired a new position in Corium International in the second quarter valued at about $1,840,000. Stonepine Capital Management LLC acquired a new position in Corium International in the second quarter valued at about $3,085,000. Finally, EAM Investors LLC acquired a new position in Corium International in the second quarter valued at about $563,000. 89.35% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/02/valuengine-upgrades-corium-international-cori-to-hold.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.